DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

Information source: Eisai Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: E3810 (Drug); Aciphex (rabeprazole) (Drug); Nexium (esomeprazole) (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Eisai Inc.

Official(s) and/or principal investigator(s):
Philip Miner, Principal Investigator, Affiliation: Oklahoma Foundation for Digestive Research, 1000 N. Lincoln, Suite 210, Oklahoma City, OK 73104 USA

Summary

This will be a randomized, open-label, single-center, 3-way crossover study in healthy subjects who are confirmed to be Helicobacter pylori (H. pylori)-negative. The study will consist of 3 study periods separated by a washout period of at least 7 days. Subjects will receive study drugs once daily for 5 days. Barring any safety concerns, subjects will be discharged from the study on Day 6 of Period 3 after completion of discharge procedures.

Clinical Details

Official title: A Randomized, Open-Label, Three-Way Crossover Study to Evaluate the Effect on 24-hour, Intragastric pH Following Daily Oral Dose Administration of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40-mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets to H. Pylori-Negative Healthy Subjects in a 5-day Treatment Regimen

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Percentage of time that intragastric pH remains >4

Secondary outcome:

Percentage of day- and night-time periods with intragastric pH >4

Number and duration of nocturnal acid breakthrough (NAB) episodes

Proportion of subjects with nocturnal acid breakthrough (NAB) episodes

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Key inclusion:

- Healthy male and female subjects, including women of child-bearing potential, aged 18

to 55 years, inclusive

- Subjects who are able to tolerate the insertion and placement of a pH probe on 2

occasions per study period (Day - 1 and Day 5)

Key Exclusion:

- Subjects who are H. pylori-positive

- Subjects who have a history of any gastrointestinal disorder or surgery likely to

influence drug absorption (e. g., history of gastric resection)

- Known hypersensitivity to rabeprazole, esomeprazole, or related compounds or any

ingredient in the formulations

- Other standard clinical pharmacology exclusion criteria for healthy volunteers

Locations and Contacts

Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma 73104, United States
Additional Information

Starting date: July 2010
Last updated: October 31, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017